A DXR-induced cardiomyopathy model was established in 32 rats. DXR was administered intraperitoneally every other day at a dose of 2.5 mg/kg/day for 6 doses. Eight rats served as the normal group without any treatment. The 32 DXR-treated rats were divided into four groups: (1) Placebo group: Received 0.9% NaCl saline solution via ip injection at 1 mL/kg/day. (2) Liraglutide group: Received liraglutide at 1.8 mg/kg/day via ip injection. (3) Oxytocin group: Received oxytocin at 160 μg/kg/day via ip injection. (4) G-CSF group: Received filgrastim (G-CSF) at 100 μg/kg/day via ip injection. Here, CSF3 is linked to cardiomyopathy.